Berenberg Bank initiated coverage on shares of RECKITT BENCKIS/S (OTCMKTS:RBGLY) in a research report sent to investors on Wednesday morning, The Fly reports. The brokerage issued a buy rating on the stock.
A number of other research firms have also recently commented on RBGLY. BNP Paribas reissued a neutral rating on shares of RECKITT BENCKIS/S in a report on Friday, July 5th. HSBC began coverage on shares of RECKITT BENCKIS/S in a report on Friday, June 28th. They issued a buy rating for the company. Zacks Investment Research raised shares of RECKITT BENCKIS/S from a sell rating to a hold rating in a report on Tuesday, July 9th. Finally, Societe Generale cut shares of RECKITT BENCKIS/S from a buy rating to a sell rating in a report on Tuesday, July 2nd. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company’s stock. RECKITT BENCKIS/S presently has a consensus rating of Hold and a consensus price target of $19.00.
RBGLY stock opened at $15.75 on Wednesday. The stock has a market capitalization of $55.84 billion, a P/E ratio of 17.50, a price-to-earnings-growth ratio of 9.16 and a beta of 0.76. RECKITT BENCKIS/S has a 12 month low of $14.42 and a 12 month high of $18.85. The firm has a 50-day moving average price of $15.82 and a 200-day moving average price of $15.89.
Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.
Further Reading: What is the role of the G-20?
Receive News & Ratings for RECKITT BENCKIS/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RECKITT BENCKIS/S and related companies with MarketBeat.com's FREE daily email newsletter.